ArticleJournal of Crohn's & colitis2015
Oral Delivery of Particulate Transforming Growth Factor Beta 1 and All-Trans Retinoic Acid Reduces Gut Inflammation in Murine Models of Inflammatory Bowel Disease.
Article in Journal of Crohn's & colitis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Interactive Effects of Vitamin A and All-Trans Retinoic Acid on Growth Performance, Intestinal Health, and Plasma Metabolomics of Broiler Chickens.Animals : an open access journal from MDPI · 2025Article
- What Happened Suddenly - Acute Abdomen? A Difficult Case of ATRA-Related Pneumatosis Cystoides IntestinalisTurkish journal of haematology : official journal of Turkish Society of Haematology · 2025Article
- Mucin Expression Profiles in Ulcerative Colitis: New Insights on the Histological Mucosal Healing.International journal of molecular sciences · 2024Article
- Lactobacillus Intestinalis Primes Epithelial Cells to Suppress Colitis-Related Th17 Response by Host-Microbe Retinoic Acid Biosynthesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Advances in engineering and delivery strategies for cytokine immunotherapy.Expert opinion on drug delivery · 2023Article
- Oral Delivery of Encapsulated All-Trans Retinoic Acid Ameliorates Disease in Rodent Models of Colitis.Inflammatory bowel diseases · 2022Article
- Oral encapsulated transforming growth factor β1 reduces endogenous levels: Effect on inflammatory bowel disease.World journal of gastrointestinal pharmacology and therapeutics · 2020Article
- Latexin deficiency in mice up-regulates inflammation and aggravates colitis through HECTD1/Rps3/NF-κB pathway.Scientific reports · 2020Article
- Retrospective follow-up analysis of the transcriptomic patterns of cytokines, cytokine receptors and chemokines at preconception and during pregnancy, in women with post-partum depression.Experimental and therapeutic medicine · 2019Article
- Upregulation of IL-1 Receptor Antagonist in a Mouse Model of Migraine.Brain sciences · 2019Article
- In vivo tracking of orally-administered particles within the gastrointestinal tract of murine models using multispectral optoacoustic tomography.Photoacoustics · 2019Article
- Nuclear Receptors Regulate Intestinal Inflammation in the Context of IBD.Frontiers in immunology · 2019Review
- Anti-Fibrotic Potential of All Trans Retinoic Acid in Inflammatory Bowel Disease.Journal of gastroenterology, pancreatology & liver disorders · 2018Article
- Review
- The Impact of Western Diet and Nutrients on the Microbiota and Immune Response at Mucosal Interfaces.Frontiers in immunology · 2017Review
- Synergy of Transforming Growth Factor Beta 1 and All Trans Retinoic Acid in the Treatment of Inflammatory Bowel Disease: Role of Regulatory T cells.Journal of gastroenterology, pancreatology & liver disorders · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
BACKGROUND AND
aimsWe investigated oral delivery of transforming growth factor beta 1 [TGFβ]- and all-trans retinoic acid [ATRA]-loaded microspheres as therapy for gut inflammation in murine models of inflammatory bowel disease [IBD].
methodsATRA and TGFβ were separately encapsulated in poly [lactic-co-glycolic] acid or polylactic acid microspheres [respectively]. TGFβ was encapsulated using proprietary phase-inversion nanoencapsulation [PIN] technology.
resultsPIN particles provided sustained release of bioactive protein for at least 4 days and were stable for up to 52 weeks when stored at either 4(0)C or -20(0)C. In the SCID mouse CD4 + CD25- T cell transfer model of IBD, oral treatment starting at disease onset prevented weight loss, significantly reduced average disease score [~ 50%], serum amyloid A levels [~ 5-fold], colon weight-to-length ratio [~ 50%], and histological score [~ 5-fold].
conclusionsBoth agents given together outperformed either separately. Highest TGFβ doses and most frequent dose schedule were most effective. Activity was associated with a significant increase [45%] in Foxp3 expression by colonic lamina propria CD4+ CD25+ T-cells. Activity was also demonstrated in dextran sulphate sodium-induced colitis. The data support development of the combination product as a novel, targeted immune based therapy for treatment for IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.